Infection à VIH-2 au Sénégal: échecs virologiques et résistances aux antirétroviraux (ARV)

Ba, Selly; Dia-Badiane, Ndèye Méry; Hawes, Stephen E.; Déguénonvo, L. Fortes; Sall, Fatima; Ndour, Cheikh Tidiane; Faye, Khadim; Traoré, Fatoumata Tata; Toure, Macoumba; Sy, Marie Pierre; Raugi, Dana N.; Kiviat, Nancy B.; Smith, Robert A.; Seydi, Moussa; Sow, Papa Salif; Gottlieb, Geoffrey S.

doi:10.11604/pamj.2019.33.222.15771

Cited by 5 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result also suggests that three out of ten patients on ART could transmit HIV to their sexual partner. Similar observations have been reported by other authors [16,17].…”

Section: Discussionsupporting

confidence: 93%

Factors Associated with Virological Suppression of HIV Viral Load in Patients on Antiretroviral Therapy in Conakry, Guinea

Camara¹,

Diallo²,

Diallo³

et al. 2022

CAJPH

View full text Add to dashboard Cite

Viral load testing is a key indicator for assessing ART success and diagnosing drug resistance in people living with HIV/AIDS on antiretroviral therapy. This study aimed to assess virological suppression among people living with HIV / AIDS on antiretroviral therapy in Guinea. This was a three years descriptive cross-sectional that involved adult HIV-positive patients treated in different sites in Conakry. The study population consisted of patients living with HIV/AIDS, followed up at Conakry ART care and treatment sites, samples collected from the study population were sent to the National Institute of Public Health for viral load testing between January 2018 and June 2021. The viral load was quantified by the Generic Biocentric technique and the detection threshold set at 350 copies/ml. Factors associated with virological suppression were analysed by univariate or multivariate logistic regression. Statistical analysis were performed by R software version R4.0.3. A total of 9815 samples were collected and viral load data analyzed at the national public health laboratory. The sample was dominated by women (72%), with an average age of 29. Of these, 6,706 (68%) of people on ART had viral load suppression. The univaried analysis showed that women were (22%) more likely to have VL suppression (p-value < 0.001) moreover, the chance for all HIV-positive people on treatment to achieve viral load suppression was related to the length of treatment. The results of this study show viral load suppression greater than 68%. The length of antiretroviral therapy, female gender, and advancing age of PLHIV were associated with VL suppression. Targeted awareness raising actions must be undertaken with patients who have an important risk.

show abstract

“…This result also suggests that three out of ten patients on ART could transmit HIV to their sexual partner. Similar observations have been reported by other authors [16,17].…”

Section: Discussionsupporting

confidence: 93%

Factors Associated with Virological Suppression of HIV Viral Load in Patients on Antiretroviral Therapy in Conakry, Guinea

Camara¹,

Diallo²,

Diallo³

et al. 2022

CAJPH

View full text Add to dashboard Cite

show abstract

“…This result also suggests that three out of ten patients could transmit the infection to their contacts even though they are all on antiretroviral treatment. Similar observations have been reported by other authors (14,16).…”

Section: Discussionsupporting

confidence: 93%

Factors Associated With Virological Suppression of HIV Viral Load in Patients on Antiretroviral Therapy in Conakry, Guinea

Camara

Diallo

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundThe viral load has become an indispensable tool in evaluating antiretroviral therapy (ART) in people living with HIV / AIDS. This study aimed to assess virological suppression among in people living with HIV / AIDS on antiretroviral therapy in Guinea.MethodsThis was a descriptive cross-sectional study of more than three years that involved adult HIV-positive patients treated in different sites in Conakry. A total of 9815 viral load data were collected. The viral load was quantified by the Generic Biocentric technique and the detection threshold set at 350 copies/ml. Statistical analyses were performed by R software version R4.0.3..ResultsA total of 9815 viral load data collected at the national public health laboratory were analysed. The sample was dominated by women (72%), with an average age of 29 [29, 39]. Of these, 6,706 (68%) of HIV-positive people on ART had viral load suppression. The univaried analysis showed that women were 22% more likely to have VL suppression (p-value <0.001) moreover, the chance for all HIV-positive people on treatment to achieve viral load suppression was related to the length of treatment.Conclusionthe results of this study show viral load suppression greater than 68%. The length of antiretroviral therapy, female gender, and advancing age of PLHIV were all favourable to VL suppression.

show abstract

“…Unlike HIV-1, HIV-2 rarely develops resistance to NRTIs through the excision pathway [ 32 ] because the presence of a methionine at position 73 in HIV-2 RT, instead of lysine as found in HIV-1, prevents the development of resistance through the accumulation of TAMs [ 64 ]. In HIV-2, nine resistance mutations (K40R, A62V, K65R, K70R, Y115F, Q151M, M184I/V, S215Y) cause significant resistance to 3TC, ABC, AZT and TDF ( Table 1 ) [ 14 , 26 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 ].…”

Section: Reverse Transcriptase Inhibitorsmentioning

confidence: 99%

Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds

Moranguinho

Taveira

Bártolo

2023

IJMS

View full text Add to dashboard Cite

Currently, it is estimated that 1–2 million people worldwide are infected with HIV-2, accounting for 3–5% of the global burden of HIV. The course of HIV-2 infection is longer compared to HIV-1 infection, but without effective antiretroviral therapy (ART), a substantial proportion of infected patients will progress to AIDS and die. Antiretroviral drugs in clinical use were designed for HIV-1 and, unfortunately, some do not work as well, or do not work at all, for HIV-2. This is the case for non-nucleoside reverse transcriptase inhibitors (NNRTIs), the fusion inhibitor enfuvirtide (T-20), most protease inhibitors (PIs), the attachment inhibitor fostemsavir and most broadly neutralizing antibodies. Integrase inhibitors work well against HIV-2 and are included in first-line therapeutic regimens for HIV-2-infected patients. However, rapid emergence of drug resistance and cross-resistance within each drug class dramatically reduces second-line treatment options. New drugs are needed to treat infection with drug-resistant isolates. Here, we review the therapeutic armamentarium available to treat HIV-2-infected patients, as well as promising drugs in development. We also review HIV-2 drug resistance mutations and resistance pathways that develop in HIV-2-infected patients under treatment.

show abstract

Infection à VIH-2 au Sénégal: échecs virologiques et résistances aux antirétroviraux (ARV)

Cited by 5 publications

References 33 publications

Factors Associated with Virological Suppression of HIV Viral Load in Patients on Antiretroviral Therapy in Conakry, Guinea

Factors Associated with Virological Suppression of HIV Viral Load in Patients on Antiretroviral Therapy in Conakry, Guinea

Factors Associated With Virological Suppression of HIV Viral Load in Patients on Antiretroviral Therapy in Conakry, Guinea

Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds

Contact Info

Product

Resources

About